Insightful Science Acquires Protein Metrics
Insightful Science has acquired Protein Metrics, a leading provider of patented proteomics and biopharmaceutical protein characterization software used by over 450 scientific enterprises, to enhance its R&D solutions by enabling highly accurate, reproducible, and scalable protein analysis across major analytical platforms, thereby addressing data bottlenecks in large-scale protein studies and expanding its portfolio alongside products like GraphPad Prism and SnapGene.
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
- Protein Metrics is market-leading software leveraged by more than 450 scientific enterprises for the large-scale study of proteins.
San Diego, CA, 21 December 2021: Insightful Science, the software company enabling the Cloud for Scientific Discovery, announced today that it has completed the transaction to acquire Protein Metrics, Inc., a leading provider of biopharmaceutical protein characterization and proteomics analysis software. The acquisition expands the company’s R&D value chain to widen the biopharmaceutical protein analysis arena, unblocking data analysis bottlenecks currently associated with large-scale protein studies.
Biotherapeutic protein characterization and proteomics are critical to innovation in biomarker and biologic drug discovery, vaccines, and therapeutic products. Protein Metrics provides a platform solution for protein analytical study from research through to industrial production. Whether it is identifying proteins for proteomics, or determining heterogeneity, Protein Metrics provides substantially more information than previous technologies, which require time consuming manual analysis by experts.
Protein Metrics’ sophisticated software allows scientists to perform highly-accurate analyses on the data generated from all major commercially available liquid chromatography, capillary electrophoresis and mass spectrometry platforms. Underpinned by 18 patents, the products’ unique algorithms are designed to help researchers minimize ambiguity, achieve reproducibility, and eliminate lab-to-lab variability.
Protein Metrics joins Insightful Science’s growing portfolio of scientific R&D software solutions, including GraphPad Prism, SnapGene, Geneious Prime, Dotmatics, and nQuery.
Eric Carlson, PhD, President & CEO of Protein Metrics commented:
"We have been committed to understanding protein science and biopharma development since our inception, and our expertise in algorithm design and software engineering aligns entirely with Insightful Science’s dedication to advancing scientific discovery. Being part of Insightful Science will allow us to continue to offer a vendor-neutral platform for our customers and to continue to invest significantly in advancing our products. We look forward to working with our new colleagues to apply novel approaches to designing data platforms and thereby give customers greater insights into their research."
Thomas Swalla, CEO of Insightful Science, added:
"We are thrilled to welcome Protein Metrics into our company and help advance our vision to build the world’s largest scientific platform that can support customers through every step of the R&D process. The acquisition of Protein Metrics expands our value chain to include proteomics – a very fast-growing and innovative area of science. With world-class technology, strong financial performance, and a team that shares a focus on customer success, we are excited about our potential to add to our capabilities and further enhance scientific execution and collaboration."
Insightful Science is a privately held portfolio company of Insight Partners, the leading global venture capital and private equity firm investing in high-growth technology and software scale-up companies.
For more information, visit https://proteinmetrics.com/
Related
Protein Metrics by Dotmatics
Protein Metrics by Dotmatics is a vendor-neutral, compliance-ready software platform trusted by over 200 biopharmaceutical companies and 300 academic institutions that accelerates protein characterization and proteomic analysis through scalable, automated, and templated workflows enabling reproducible biotherapeutic reporting, deep data insights, seamless transition between non-GxP and GxP environments, and efficient knowledge sharing across discovery and regulated settings.
Luma Antibody & Protein Engineering Solution for End-to-End Antibody Discovery
Dotmatics has launched the Luma Antibody & Protein Engineering Solution, the first in its Luma Multimodal R&D Solutions series, which integrates the Dotmatics Luma Scientific Intelligence Platform with key tools like Geneious, GraphPad Prism, and others to streamline and unify antibody discovery and development—particularly for monoclonal and multispecific antibodies—while supporting a broad range of therapeutic modalities including CAR-T, siRNA, ADCs, CRISPR, and vaccines within a collaborative, multimodal research environment.
How Bispecific Antibodies Are Changing the Treatment of Complex Diseases
Bispecific antibodies, an advanced form of antibody therapeutics derived from the natural IgG structure, are revolutionizing the treatment of complex and treatment-resistant diseases by enabling simultaneous targeting of two different antigens, thereby expanding the possibilities of personalized immunotherapy in a rapidly growing market.
Dotmatics Mini-Summit: From Insights to Impact
The Dotmatics Mini-Summit: From Insights to Impact is a 90-minute digital event featuring CEO Thomas Swalla and experts demonstrating Dotmatics Luma, a no-code, multimodal data platform that automates aggregation of diverse research data from thousands of instruments and software, enables easy data modeling, streamlines scientific workflows, offers upcoming AI-powered natural language search, and supports FAIR data principles, followed by a live Q&A session.
Data Management, Collaboration, and Workflow Optimisation: The Three Keys to Small Molecule Discovery Success
The article emphasizes that despite biologics' prominence, small molecule drug discovery is experiencing a renaissance driven by advances in screening, target exploration, and AI, but overcoming challenges like rising costs, data management, fragmented workflows, and CRO reliance requires success in three key areas: next-generation data management, enhanced cross-disciplinary research collaboration, and workflow optimization.
BioGlyph Luma: Protein Design and Computational Modeling Platform
BioGlyph Luma is a next-generation protein design platform that integrates molecular modeling, production, and characterization into a seamless, traceable workflow, automates data management by converting LC-MS data into actionable insights, and connects with industry-standard tools to accelerate biologic discovery and optimize precision in protein and antibody engineering.